

REPROS THERAPEUTICS INC.

Form 8-K

February 12, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report  
(Date of earliest event reported): February 12, 2008  
Repos Therapeutics Inc.  
(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>001-15281</b>	<b>76-0233274</b>
<b>(State or other jurisdiction of incorporation or organization)</b>	<b>(Commission File Number)</b>	<b>(I.R.S. Employer Identification No.)</b>
	<b>2408 Timberloch Place, Suite B-7 The Woodlands, Texas 77380 (Address of principal executive offices and zip code) (281) 719-3400 (Registrant's telephone number, including area code)</b>	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure**

Repros Therapeutics Inc. is furnishing herewith as Exhibit 99.1 a copy of a slide show presentation that it intends to present on Tuesday, February 12, 2008 at 1:15 pm Eastern Time at the 10<sup>th</sup> Annual Bio/CEO and Investor Conference. These slides contain statements that are forward-looking statements subject to the cautionary statement about forward-looking statements set forth therein.

The information in this Current Report, including the Exhibit, is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. In addition, the information in this Current Report, including the Exhibit, shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933

**Item 9.01. Financial Statements and Exhibits**

c. Exhibits

Exhibit Number	Description
99.1	Repros Therapeutics Inc. slide show.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: February 12, 2008

By: /s/ Louis Ploth, Jr.  
Louis Ploth, Jr.  
Vice President, Business  
Development and  
Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Repros Therapeutics Inc. slide show